NASDAQ NMS - GLOBAL MARKET · CABA
+1.14% · +$0.0308 · Vol 2.7M
After hours · updated 18:36:01 ET
Cabaletta Bio Inc

Cabaletta Bio Inc

Biotechnology
$2.74
Card
Relationship Map

Veridion Score

BETAMEDIUM CONF · 5/6 factorsMethodology
CABA
Cabaletta Bio Inc
Thu Aug 6 · session closed · Markets closed · resumes Fri 9:30 ET
BUY BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

62/ 100
Veridion Score
BUY BIAS · MEDIUM confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 5/6 factors with data · Thu Aug 6 · session closed · Markets closed · resumes Fri 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is CABA moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading CABA catalysts
About Cabaletta Bio Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2019
Employees
158
Country
US

Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$2.68
Day high
$2.82
Day low
$2.66
Previous close
$2.71
52W high
$4.15
-33.96% from high
52W low
$1.33
50% of range
Market cap
$441.9M
EPS
$-2.2700
Beta
1.16
Shares out
163.1M
Volume
2.7M
0.57× rel vol
Avg volume
4.8M
VWAP
$2.77
Price history computed in-house
1W
+0.76%
1M
-11.59%
3M
-29.36%
1Y
+89.02%
YTD
+25.15%
SMA 50 $3.01 · below
SMA 200 $2.86 · below
52W position 50%

CABA overview

Veridion Score
62
5 of 6 factors measured
Congress receipts
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around CABA.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading CABA Form 4 filings
Public disclosures

Congress activity in CABA

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for CABA in the cached public ledger.

Federal contracts

CABA contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for CABA in this window.
Lobbying spend

CABA lobbying filings, year to date.

Registered lobbying filings matched to Cabaletta Bio Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for CABA in this window.
Loading news for CABA
Analyst ratings
Sovereign unlock shows live analyst consensus for CABA.
Options
Sovereign unlock shows live options positioning for CABA.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.